- Home
- BXSL vs IONS Comparison
BXSL vs IONS Comparison
Compare BXSL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXSL
- IONS
- Stock Information
- Founded
- BXSL 2018
- IONS 1989
- Country
- BXSL United States
- IONS United States
- Employees
- BXSL N/A
- IONS N/A
- Industry
- BXSL Trusts Except Educational Religious and Charitable
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- BXSL Finance
- IONS Health Care
- Exchange
- BXSL Nasdaq
- IONS Nasdaq
- Market Cap
- BXSL 7.3B
- IONS 5.9B
- IPO Year
- BXSL N/A
- IONS 1991
- Fundamental
- Price
- BXSL $30.87
- IONS $39.94
- Analyst Decision
- BXSL Buy
- IONS Buy
- Analyst Count
- BXSL 6
- IONS 16
- Target Price
- BXSL $31.38
- IONS $58.25
- AVG Volume (30 Days)
- BXSL 911.4K
- IONS 1.7M
- Earning Date
- BXSL 08-06-2025
- IONS 07-31-2025
- Dividend Yield
- BXSL 10.01%
- IONS N/A
- EPS Growth
- BXSL N/A
- IONS N/A
- EPS
- BXSL 3.14
- IONS N/A
- Revenue
- BXSL $1,380,706,000.00
- IONS $717,253,000.00
- Revenue This Year
- BXSL $9.58
- IONS $7.98
- Revenue Next Year
- BXSL $3.71
- IONS $16.09
- P/E Ratio
- BXSL $9.81
- IONS N/A
- Revenue Growth
- BXSL 16.76
- IONS N/A
- 52 Week Low
- BXSL $25.89
- IONS $23.95
- 52 Week High
- BXSL $34.64
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- BXSL 38.92
- IONS 74.06
- Support Level
- BXSL $30.40
- IONS $39.37
- Resistance Level
- BXSL $31.71
- IONS $40.61
- Average True Range (ATR)
- BXSL 0.46
- IONS 1.12
- MACD
- BXSL -0.13
- IONS 0.21
- Stochastic Oscillator
- BXSL 10.28
- IONS 85.43
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.